胎盘来源结缔组织基质促进小鼠喉返神经再生
本研究旨在量化商用胎盘来源结缔组织基质(pd-CTM)中的细胞因子,并探讨其在小鼠单侧喉返神经损伤模型中对声带微环境和声门功能的影响。结果显示pd-CTM含多种神经营养、血管生成、组织重塑和抗炎因子,治疗组在28天时喉肌电图显示再支配增加(p < 0.001),免疫组化检出神经支配的神经肌肉接头。pd-CTM可能成为单侧声带麻痹的新治疗选择。
要点
- pd-CTM含BDNF、CNTF、GDNF、NTF-3等神经营养因子及多种抗炎因子。
- 小鼠喉返神经切断后注射pd-CTM,28天喉肌电图提示再支配增加。
- pd-CTM或为单侧声带麻痹提供新型生物治疗注射选项。
核心结论
- pd-CTM具有神经营养、血管生成、组织重塑和抗炎因子,可能成为单侧声带麻痹的新型治疗选择。
研究设计与样本
- 研究先使用细胞因子阵列和ELISA定量pd-CTM中的细胞因子表达(ng/mL)。
- 随后将C57/BL6小鼠分为三组:未损伤阴性对照组(n=12)、喉返神经切断加同侧声带肌生理盐水注射组(n=16)、喉返神经切断加同侧声带肌pd-CTM注射组。
- 结局指标包括第7天和第28天的喉肌电图和视频喉镜,随后取喉组织进行免疫组化和qPCR分析。
主要发现
- pd-CTM中检出中至高水平的BDNF、CNTF、GDNF、NTF-3等神经营养因子,Angiogenin、VEGF-D等血管生成因子,bFGF、IGF-1、HGF、TGF-β3等组织重塑因子,以及IL-10、IL-1Rα等抗炎因子。
- 第28天时,pd-CTM治疗组小鼠的平均归一化曲线下面积比较生理盐水组增加(p < 0.001),提示再支配。
- pd-CTM治疗后28天,免疫组化检出神经支配的神经肌肉接头。
关键数值与推荐
- pd-CTM中神经营养因子、血管生成因子、组织重塑因子和抗炎因子的表达水平以ng/mL定量。
- 喉肌电图再支配评估:第28天pd-CTM组较生理盐水组平均归一化曲线下面积比增加,p < 0.001。
临床怎么用
- pd-CTM作为声带肌内注射生物治疗,可能促进喉返神经损伤后的再支配,但当前证据仅来自小鼠模型。
局限性
- 研究为小鼠模型,样本量有限,结果外推到人类需进一步验证。
- 证据等级为NA。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Unilateral vocal fold paralysis (UVFP) due to recurrent laryngeal nerve (RLN) injury is a common cause of dysphonia. No biotherapeutic injectable exists that directs laryngeal reinnervation after RLN injury. Placental-derived connective tissue matrix (pd-CTM) could fill this need, as it contains a plethora of cytokines with potential UVFP therapeutic benefits. This study aimed to identify and quantify the factors in a commercially available pd-CTM (CTM Flow, CTM Biomedical, Lake Worth, Florida) and to study the effects of pd-CTM on vocal fold microenvironment and glottic function in a mouse model of unilateral RLN injury. METHODS: Cytokine expression (ng/mL) in pd-CTM was characterized using a cytokine array and ELISA. In a separate experiment, C57/BL6 mice were divided into three groups: uninjured negative controls (n = 12), RLN transection with ipsilateral saline thyroarytenoid (TA) injection (n = 16), and RLN transection with ipsilateral pd-CTM TA injection. Outcomes included laryngeal electromyography (L-EMG) and video laryngoscopy after 7 and 28 days, with larynges then harvested and analyzed via immunohistochemistry (IHC) and qPCR. RESULTS: pd-CTM characterization showed moderate-to-high levels of neurotrophic (BDNF, CNTF, GDNF, NTF-3), angiogenic (Angiogenin, VEGF-D), tissue remodeling (bFGF, IGF-1, HGF, TGF-β3), and anti-inflammatory factors (IL-10, IL-1Rα). L-EMG demonstrated increased mean normalized area under the curve ratio in pd-CTM treated mice compared to saline treated mice at the 28-day time point indicating reinnervation (p < 0.001). IHC detected innervated neuromuscular junctions 28 days after pd-CTM treatment. CONCLUSION: pd-CTM may be a novel treatment option for patients with UVFP based on the neurotrophic, angiogenic, tissue remodeling, and anti-inflammatory factors present. LEVEL OF EVIDENCE: NA.
引用
- Anekal S, Tadikonda A, Sobczak G, et al. Placental-Derived Connective Tissue Matrix Mediates Murine Recurrent Laryngeal Nerve Regeneration. Laryngoscope. 2025. PMID: 41424184. doi:10.1002/lary.70313
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。